A Diabetes Drug May Be the Key to Treating a Silent Liver Crisis
What started as a medication for blood sugar control is now catching the eye of liver specialists around the world. Semaglutide—better known to the public by its brand names Ozempic, Wegovy, and Rybelsus—is moving beyond diabetes and weight loss, stepping into the challenging territory of liver disease with encouraging results.
A sweeping new phase 3 clinical trial, published in The New England Journal of Medicine, sheds light on the potential of semaglutide to slow or even reverse metabolic dysfunction-associated steatohepatitis (MASH), an advanced form of fatty liver disease previously known as NASH. This is not your garden-variety fatty liver; it’s a progressive, inflammation-driven condition that can lead to fibrosis, cirrhosis, and, ultimately, liver failure.
Inside the Study: 800 Patients, 37 Countries, One Question
Could semaglutide change the trajectory of MASH?
To find out, researchers recruited 800 adults from 37 countries—all with biopsy-confirmed MASH and varying degrees of liver fibrosis. More than half had type 2 diabetes. Nearly three-quarters had obesity. These patients were randomly assigned weekly injections: 534 received semaglutide, while 266 got a placebo. For 72 weeks, researchers tracked two key metrics: whether inflammation in the liver subsided without fibrosis worsening, and whether scarring (fibrosis) improved without inflammation escalating.
The results? Striking. Nearly two-thirds of those on semaglutide saw resolution of steatohepatitis, while fibrosis remained stable. Just over a third saw improvements in fibrosis. And a remarkable 33% saw both—compared to only 16% of the placebo group.
Beyond the Liver: Weight Loss, Inflammation, and Cholesterol
As expected, semaglutide helped participants shed weight. The average drop was 10.5% of body mass, compared to just 2% in the placebo arm. This weight loss may play a critical role. Experts suspect that many of semaglutide’s liver benefits stem directly from the weight patients lose, rather than the drug acting directly on liver tissue.
But weight wasn’t the only win. The semaglutide group also showed improvements in liver stiffness, systemic inflammation, insulin sensitivity, and cholesterol levels. While adverse effects—primarily gastrointestinal—were slightly more common with semaglutide, researchers reported no unexpected liver-related safety concerns.
The Fine Print: What We Still Don’t Know
Despite the optimistic findings, the study isn’t without limits. Black and lean participants were underrepresented, and researchers did not track alcohol biomarkers or fully account for the influence of genetics. This trial also only reports the first phase of a larger ongoing study, which will later evaluate whether semaglutide improves long-term outcomes like cirrhosis-free survival.
Crucially, experts emphasize that while semaglutide appears to support liver health, it may be acting indirectly by tackling metabolic dysfunction—the root of MASH. As Dr. Mir Ali, a bariatric surgeon not affiliated with the study, noted, “Weight loss is a powerful lever. In our surgical patients, we see liver health bounce back significantly when patients lose enough weight.”
A New Frontier in Liver Care
Dr. Ian Storch, a gastroenterologist, praised the study’s implications, noting that MASH has long been neglected due to a lack of both cost-effective diagnostic tools and effective treatments. “This study represents a major step forward in addressing an indolent but deadly disease,” he said.
The takeaway? We may be witnessing a shift. Semaglutide, once a diabetes drug, then a weight loss marvel, may now be positioned as a multipurpose treatment in the fight against metabolic diseases—including liver damage that has, for too long, flown under the radar.
As longer-term data emerges, clinicians are watching closely. If semaglutide continues to perform well, it could reshape the standard of care for millions silently living with liver disease.
